Miguel Gonzalez Velez: Japanese Real-World Comparison of Atezolizumab and Durvalumab in Extensive-Stage SCLC
Miguel Gonzalez Velez/regionalcancercare.org

Miguel Gonzalez Velez: Japanese Real-World Comparison of Atezolizumab and Durvalumab in Extensive-Stage SCLC

Miguel Gonzalez Velez, Medical Oncologist at John Theurer Cancer Center , University Medical Center, shared on X:

“Atezolizumab versus durvalumab plus platinum etoposide in extensive stage SCLC by Hirano and colleagues on JJCO.

Take: Japan real-world, propensity-matched n=128, mOS 13.9 vs 14.8 mo, p=0.92;

  • monthly cost $7,183 vs $11,422;
  • grade 2 or higher irAE 11% vs 31%;
  • ILD 3% vs 20%.

Miguel Gonzalez Velez: Japanese Real-World Comparison of Atezolizumab and Durvalumab in Extensive-Stage SCLC

Same survival, but atezolizumab was cheaper and notably less pneumonitis. I think this will be an interesting idea to develop between IMforte and Dellphi 305 does the immunotherapy backbone matter? Also might be useful in countries that cost is a limitation.”

Title: Atezolizumab vs durvalumab for extensive-stage small cell lung cancer in Japan: a real-world comparative analysis of costs and clinical outcomes

Authors: Katsuya Hirano, Akito Hata, Yuta Yamanaka, Toshiyuki Sumi, Motohiro Tamiya, Yuki Sato, Yuko Oya, Kosuke Hamai, Nobuyuki Katakami, Katsuhiko Iwasaki, Tatsuhiro Uenishi, Kinya Kokubo, Ataru Igarashi

 

Read the full article.

Miguel Gonzalez Velez: Japanese Real-World Comparison of Atezolizumab and Durvalumab in Extensive-Stage SCLC